# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-057542
Filing Date
2021-04-29
Accepted
2021-04-29 16:04:06
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm212689d2_defa14a.htm | DEFA14A | 20838
2 | GRAPHIC | tm212689d2_defa14aimg001.jpg | GRAPHIC | 519929
3 | GRAPHIC | tm212689d2_defa14aimg002.jpg | GRAPHIC | 352528
| Complete submission text file | 0001104659-21-057542.txt |  | 1223804

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 21870401
SIC: 2834 Pharmaceutical Preparations